...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children.
【24h】

Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children.

机译：过敏性接触性皮炎在特应性皮炎中进行局部治疗的患病率和危险因素：一项针对641名儿童的研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: There is little information regarding the risk of sensitization associated with topical atopic dermatitis (AD) treatment. OBJECTIVES: To assess the frequency of sensitization to topical treatment of AD in children and to determine risk factors associated with skin sensitization. METHODS: Six hundred and forty-one children with AD were systematically patch tested with seven agents of common topical treatment: chlorhexidine, hexamidine, budesonide, tixocortol pivalate, bufexamac, sodium fusidate and with the current emollient used by the child. The following variables were recorded: age, sex, age at onset of AD, associated asthma, severity of AD, and history of previous exposure to topical agents used in the treatment of AD. Skin prick tests to inhalant and food allergens were used to explore the IgE-mediated sensitization. RESULTS: Forty-one positive patch tests were found in 40 patients (6.2%). Allergens were emollients (47.5%), chlorhexidine (42.5%), hexamidine (7.5%), tixocortol pivalate and bufexamac (2.5% each). Risk factors associated with sensitization to AD treatment were AD severity [OR: 3.3; 95% confidence interval (CI):1.5-7.1 for moderate to severe AD], AD onset before the age of 6 months (OR: 2.7; 95% CI: 1.2-6.1), and IgE-mediated sensitization (OR: 2.5; 95% CI: 1.1-5.9). CONCLUSIONS: Topical treatment of AD is associated with cutaneous sensitization. Antiseptics and emollients represent the most frequent sensitizers and may be included in the standard series in AD children when contact dermatitis is suspected. Risk factors associated with sensitization to AD topical treatments are AD severity, early AD onset and IgE-mediated sensitization.
机译：背景：关于局部特应性皮炎（AD）治疗相关致敏风险的信息很少。目的：评估对儿童AD局部治疗的致敏频率，并确定与皮肤致敏相关的危险因素。方法：对614名患有AD的儿童进行了系统的贴片测试，其中使用了七种常见的局部治疗药物：洗必泰，己hexa，布地奈德，替考特新戊酸酯，bufexamac，夫西地酸钠以及该儿童目前使用的润肤剂。记录以下变量：年龄，性别，AD发作年龄，相关哮喘，AD严重程度以及先前接触过用于AD治疗的局部用药史。对吸入剂和食物过敏原的皮肤点刺试验用于探索IgE介导的致敏作用。结果：40名患者（6.2％）发现了41个阳性斑贴试验。变应原是润肤剂（47.5％），洗必太（42.5％），己（（7.5％），替考克特戊新戊酸酯和布非昔马克（各2.5％）。与对AD治疗敏感相关的危险因素为AD严重程度[OR：3.3;中度至重度AD的95％置信区间（CI）：1.5-7.1]，6个月之前的AD发作（OR：2.7; 95％CI：1.2-6.1）和IgE介导的致敏作用（OR：2.5; 95％CI：1.1-5.9）。结论：AD的局部治疗与皮肤敏化有关。怀疑接触性皮炎时，防腐剂和润肤剂是最常见的敏化剂，并可能包含在AD儿童的标准系列中。与AD局部治疗致敏相关的危险因素为AD严重程度，AD早期发作和IgE介导的致敏作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号